Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | EP300 | Q09472 | 1/20 | 0.44 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.44 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.44 |
| ▸ | ERN1 | O75460 | 1/20 | 0.43 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.41 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.41 |
| ▸ | ESR1 | P03372 | 2/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.41 |
| ▸ | CLK1 | P49759 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.39 |
| ▸ | P4HB | P07237 | 1/20 | 0.39 |
| ▸ | TNF | P01375 | 1/20 | 0.38 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.38 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.38 |
| ▸ | AXL | P30530 | 1/20 | 0.36 |
| ▸ | DAO | P14920 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1705663 | 0.84 | IMPDH2 (0.61) | POLBEP300KAT2BKAT8ERN1 | |
| SCHEMBL29828616 | 0.84 | IMPDH2 (0.61) | POLBEP300KAT2BKAT8ERN1 | |
| SCHEMBL1650438 | 0.79 | PTPN22 (0.50) | POLBEP300KAT2BKAT8ERN1 | |
| Bromide SCHEMBL9548953 | 0.78 | PTPN22 (0.48) | POLBEP300KAT2BKAT8ERN1 | |
| SCHEMBL3714977 | 0.76 | IMPDH2 (0.72) | POLBEP300KAT2BKAT8IMPDH2 | |
| SCHEMBL27040501 | 0.76 | IMPDH2 (0.43) | POLBIMPDH2KDM4EMAPK10CLK1 | |
| SCHEMBL30709993 | 0.76 | IMPDH2 (0.43) | POLBIMPDH2KDM4EMAPK10CLK1 | |
| SCHEMBL15058583 | 0.76 | IMPDH2 (0.43) | POLBIMPDH2KDM4EMAPK10CLK1 | |
| SCHEMBL21050856 | 0.76 | IMPDH2 (0.43) | POLBIMPDH2KDM4EMAPK10CLK1 | |
| SCHEMBL29751463 | 0.76 | IMPDH2 (0.43) | POLBIMPDH2KDM4EMAPK10CLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101941977-A | The antitumoral analogue of stratiform element | PHARMA MAR SAU | 2011-01-12 | — | — | CN | disclosed |
| EP-1551844-B1 | ANTITUMORAL ANALOGS OF LAMELLARINS | PHARMA MAR SAU (ES) | 2010-07-28 | — | — | EP | disclosed |
| EP-2138496-A1 | Antitumoral analogs of lamellarins | Pharma Mar, S.A.U. (ES) | 2009-12-30 | — | — | EP | disclosed |
| US-7396837-B2 | Antitumoral analogs of lamellarins | PHARMA MAR, S.A.U. (ES) | 2008-07-08 | — | — | US | disclosed |
| US-20060173030-A1 | Antitumoral analogs of lamellarins | PHARMA MAR, S.A.U. (ES) | 2006-08-03 | — | — | US | disclosed |
| CN-1688585-A | Antitumor analogs of lamellarins | PHARMA MAR SAU (ES) | 2005-10-26 | — | — | CN | disclosed |
| EP-1551844-A2 | ANTITUMORAL ANALOGS OF LAMELLARINS | Pharma Mar, S.A.U. (ES) | 2005-07-13 | — | — | EP | disclosed |
| WO-2004014917-A2 | ANTITUMORAL ANALOGS OF LAMELLARINS | PHARMA MAR, S.A.U. (ES) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060173030-A1 | Antitumoral analogs of lamellarins | PLIN3, LPAR3, LPAR2 | POLB 664/4885EP300 2666/4885KAT2B 1129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.